Novo Nordisk A S (NVO) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Novo Nordisk A S (NVO) stock forecast summary
Our AI ranks Novo Nordisk A S outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Novo Nordisk A S is a large-cap company with a market capitalization of $169.41B. It ranks number 8 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its ROE of 176.6% is the highest of the 34 peers that report one. Its Current Ratio of 0.80x is the lowest of the 55 peers that report one.
For NVO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.6%, buy ≥ +3.2%, sell < +1.9%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NVO included.
Follow NVO freeNVO price chart and AI forecast
How NVO ranks among 5112 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Novo Nordisk A S (NVO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in DKK and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | NVO | Rank |
|---|---|---|
| Market Cap | $169.41B | 8/60 |
| P/E Ratio | 2.83x | 28/29 |
| EPS | $13.48 | – |
| Revenue/Share | $34.48 | – |
| FCF/Share | $9.66 | – |
Profitability & Margins
| Metric | NVO | Rank |
|---|---|---|
| ROE | 176.6% | 1/34 |
| ROA | 63.1% | 1/40 |
| ROIC | 132.4% | 1/43 |
| Gross Margin | 83.4% | 16/33 |
| Operating Margin | 43.0% | 5/36 |
| Net Margin | 34.0% | 5/33 |
| EBT Margin | 42.8% | 7/43 |
| Tax Rate | 20.6% | – |
Financial Health
| Metric | NVO | Rank |
|---|---|---|
| Current Ratio | 0.80x | 55/55 |
| Quick Ratio | 0.57x | 40/41 |
| D/E Ratio | 1.80x | 13/45 |
| Financial Leverage | 2.80x | 12/44 |
| Working Capital | -$6.79B | 54/55 |
Cash Flow
| Metric | NVO | Rank |
|---|---|---|
| Operating Cash Flow | $64.99B | 1/54 |
| Free Cash Flow | $42.93B | 2/46 |
| Capital Spending | -$22.06B | 46/46 |
| OCF Growth YoY | 115.7% | 6/32 |
| FCF Growth YoY | 0.0% | 16/29 |
| FCF/Sales | 28.0% | 9/39 |
| CapEx/Sales | 14.4% | 6/39 |
Operational Efficiency
| Metric | NVO | Rank |
|---|---|---|
| Asset Turnover | 1.86x | 2/39 |
| Inventory Turnover | 3.4x | 8/33 |
| Days Inventory | 108 days | 26/33 |
Income Statement
| Metric | NVO | Rank |
|---|---|---|
| Total Revenue | $153.22B | 2/43 |
| Operating Income | $65.83B | 1/46 |
| Net Income | $52.04B | 1/42 |
| R&D Expense | $23.79B | 5/53 |
| Cost of Goods Sold | $25.45B | 5/33 |
Dividend & Shareholder Information
| Metric | NVO | Rank |
|---|---|---|
| Shares Outstanding | 4444M | – |
| Net Income Growth | 104.6% | 1/12 |
| EPS Growth | 24.9% | 7/19 |
Balance Sheet Highlights (USD millions, converted from DKK)
| Total Current Assets | $27.12B | |
| Cash & Short-term Investments | $4.16B | |
| Inventory | $7.80B | |
| Total Liabilities | $54.86B |
NVO quarterly financials and insider trading
Novo Nordisk A S (NVO) industry peers
Companies classified under the same SEC industry code as Novo Nordisk A S (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NVO Novo Nordisk A S | ▼ | $169.41B |
| LLY Eli Lilly & Co | ▼ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ABBV Abbvie Inc. | ▼ | $500.94B |
| MRK Merck & Co., Inc. | ▼ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| AZN Astrazeneca Plc | ▼ | $251.15B |
| ABT Abbott Laboratories | ▼ | $179.05B |
| PFE Pfizer Inc | ▼ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▼ | $121.09B |
| GSK Gsk Plc | ▼ | $96.58B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $80.48B |
| SNY Sanofi | ▼ | $48.50B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| ONC Beone Medicines Ltd. | ▲ | $39.96B |
| RPRX Royalty Pharma Plc | ▶ | $33.92B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $30.04B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▶ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.28B |
| GMAB Genmab A/S | ▶ | $23.73B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▲ | $14.97B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| ELAN Elanco Animal Health Inc | ▶ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.82B |
| CYTK Cytokinetics Inc | ▲ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.50B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B |
| ABVX Abivax S.A. | ▼ | $7.68B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.67B |
| ALKS Alkermes Plc. | ▲ | $6.56B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B |
| BLTE Belite Bio, Inc | ▲ | $6.01B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $5.08B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▲ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $4.03B |
Where NVO sits on the market map
Novo Nordisk A S (NVO) stock news
Loading...
Novo Nordisk A S (NVO) stock forecast FAQ
What is the Novo Nordisk A S (NVO) stock forecast?
Our AI ranks Novo Nordisk A S outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Novo Nordisk A S stock predictions?
For NVO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Novo Nordisk A S forecasts updated?
Novo Nordisk A S forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Novo Nordisk A S's industry peers?
60 issuers in our coverage, NVO included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.